Journal of Biological Chemistry · 2006 · 79 citations · 47 references
Life SciencesBiochemistryPhysiologyEnzymologyMetabolismRedox BiochemistryAntioxidant DefenseLipid PeroxidationOxidative StressRedox EnzymesRedox MetabolismCellular Metabolism In IschemiaEnzyme Activity RegulationEnzyme Redox ActivationEnzyme-mediated Redox ActivationFree Radical ScavengingOxidative Stress InjuryRedox-dependent ActivationThiol Chemistry
Aldose reductase (AR) reduces cytotoxic aldehydes and glutathione conjugates of aldehydes derived from lipid peroxidation. Its inhibition has been shown to increase oxidative injury and abolish the late phase of ischemic preconditioning. However, the mechanisms by which ischemia regulates AR activity remain unclear. Herein, we report that rat hearts subjected to ischemia, in situ or ex vivo, display a 2–4-fold increase in AR activity. The AR activity was not further enhanced by reperfusion. Activation increased Vmax of the enzyme without affecting the Km and decreased the sensitivity of the enzyme to inhibition by sorbinil. Enzyme activation could be prevented by pretreating the hearts with the radical scavenging thiol, N-(2-mercaptoproprionyl)glycine or the superoxide dismutase mimetic, Tiron, or by treating homogenates with dithiothreitol. In vitro, the recombinant enzyme was activated upon treatment with H2O2 and the activated, but not the native enzyme, formed a covalent adduct with the sulfenic acid-specific reagent dimedone. The enzyme activity in the ischemic, but not the nonischemic heart homogenates was inhibited by dimedone. Separation of proteins from hearts subjected to coronary occlusion by two-dimensional electrophoresis and subsequent matrix-assisted laser desorption ionization time-of-flight/mass spectrometry analysis revealed the formation of sulfenic acids at Cys-298 and Cys-303. These data indicate that reactive oxygen species formed in the ischemic heart activate AR by modifying its cysteine residues to sulfenic acids. Aldose reductase (AR) reduces cytotoxic aldehydes and glutathione conjugates of aldehydes derived from lipid peroxidation. Its inhibition has been shown to increase oxidative injury and abolish the late phase of ischemic preconditioning. However, the mechanisms by which ischemia regulates AR activity remain unclear. Herein, we report that rat hearts subjected to ischemia, in situ or ex vivo, display a 2–4-fold increase in AR activity. The AR activity was not further enhanced by reperfusion. Activation increased Vmax of the enzyme without affecting the Km and decreased the sensitivity of the enzyme to inhibition by sorbinil. Enzyme activation could be prevented by pretreating the hearts with the radical scavenging thiol, N-(2-mercaptoproprionyl)glycine or the superoxide dismutase mimetic, Tiron, or by treating homogenates with dithiothreitol. In vitro, the recombinant enzyme was activated upon treatment with H2O2 and the activated, but not the native enzyme, formed a covalent adduct with the sulfenic acid-specific reagent dimedone. The enzyme activity in the ischemic, but not the nonischemic heart homogenates was inhibited by dimedone. Separation of proteins from hearts subjected to coronary occlusion by two-dimensional electrophoresis and subsequent matrix-assisted laser desorption ionization time-of-flight/mass spectrometry analysis revealed the formation of sulfenic acids at Cys-298 and Cys-303. These data indicate that reactive oxygen species formed in the ischemic heart activate AR by modifying its cysteine residues to sulfenic acids. Aldose reductase (AR) 2The abbreviations used are: AR, aldose reductase; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate; DTT, dithiothreitol; KH buffer, Krebs-Henseleit buffer; MPG, N-(2-mercaptoproprionyl)glycine; NEM, N-ethylmaleimide; ROS, reactive oxygen species; MALDI-TOF/MS, matrix-assisted laser desorption ionization time-of-flight/mass spectrometry; ESI, electrospray ionization.2The abbreviations used are: AR, aldose reductase; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate; DTT, dithiothreitol; KH buffer, Krebs-Henseleit buffer; MPG, N-(2-mercaptoproprionyl)glycine; NEM, N-ethylmaleimide; ROS, reactive oxygen species; MALDI-TOF/MS, matrix-assisted laser desorption ionization time-of-flight/mass spectrometry; ESI, electrospray ionization. is an efficient catalyst for the reduction of glucose and a wide range of aldehydes derived from lipid peroxidation (1Srivastava S. Watowich S.J. Petrash J.M. Srivastava S.K. Bhatnagar A. Biochemistry. 1999; 38: 42-54Crossref PubMed Scopus (151) Google Scholar, 2Srivastava S.K. Ramana K.V. Bhatnagar A. Endocr. Rev. 2005; 26: 380-392Crossref PubMed Scopus (401) Google Scholar). The enzyme also catalyzes the reduction of glutathione conjugates of unsaturated aldehydes such as acrolein, 4-hydroxy-trans-2-nonenal, and trans-2-hexenal with higher efficiency than the parent aldehyde (3Dixit B.L. Balendiran G.K. Watowich S.J. Srivastava S. Ramana K.V. Petrash J.M. Bhatnagar A. Srivastava S.K. J. Biol. Chem. 2000; 275: 21587-21595Abstract Full Text Full Text PDF PubMed Scopus (83) Google Scholar, 4Ramana K.V. Dixit B.L. Srivastava S. Balendiran G.K. Srivastava S.K. Bhatnagar A. Biochemistry. 2000; 39: 12172-12180Crossref PubMed Scopus (92) Google Scholar). Our recent studies suggest that AR participates also in the metabolism of 1-palmitoyl-2-oxovaleroyl phosphatidylcholine and related phospholipid (“core”) aldehydes (5Srivastava S. Spite M. Trent J.O. West M.B. Ahmed Y. Bhatnagar A. J. Biol. Chem. 2004; 279: 53395-53406Abstract Full Text Full Text PDF PubMed Scopus (67) Google Scholar) generated upon oxidation of unsaturated fatty acids esterified to the sn-2 position of phospholipids. The efficacy of AR in reducing multiple aldehydes suggests that the enzyme may be involved in cellular defense against aldehydes produced by lipid peroxidation. The notion that AR is involved in antioxidant defense is supported by evidence showing that: the AR gene is induced by oxidants such as aldehydes (6Ruef J. Liu S.Q. Bode C. Tocchi M. Srivastava S. Runge M.S. Bhatnagar A. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1745-1752Crossref PubMed Scopus (93) Google Scholar, 7Spycher S.E. Tabataba-Vakili S. O'Donnell V.B. Palomba L. Azzi A. FASEB J. 1997; 11: 181-188Crossref PubMed Scopus (150) Google Scholar) and hydrogen peroxide (7Spycher S.E. Tabataba-Vakili S. O'Donnell V.B. Palomba L. Azzi A. FASEB J. 1997; 11: 181-188Crossref PubMed Scopus (150) Google Scholar, 8Keightley J.A. Shang L. Kinter M. Mol. Cell. Proteomics. 2004; 3: 167-175Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar) and under conditions associated with oxidative stress such as myocardial ischemia (9Shinmura K. Bolli R. Liu S.Q. Tang X.L. Kodani E. Xuan Y.T. Srivastava S. Bhatnagar A. Circ. Res. 2002; 91: 240-246Crossref PubMed Scopus (112) Google Scholar), heart failure (10Yang J. Moravec C.S. Sussman M.A. DiPaola N.R. Fu D. Hawthorn L. Mitchell C.A. Young J.B. Francis G.S. McCarthy P.M. Bond M. Circulation. 2000; 102: 3046-3052Crossref PubMed Scopus (191) Google Scholar), vascular inflammation (11Rittner H.L. Hafner V. Klimiuk P.A. Szweda L.I. Goronzy J.J. Weyand C.M. J. Clin. Investig. 1999; 103: 1007-1013Crossref PubMed Scopus (193) Google Scholar), and alcoholic liver disease (12O'Connor T. Ireland L.S. Harrison D.J. Hayes J.D. Biochem. J. 1999; 343: 487-504Crossref PubMed Scopus (187) Google Scholar); and that inhibition of AR increases aldehyde toxicity in rat vascular smooth muscle cell lines (7Spycher S.E. Tabataba-Vakili S. O'Donnell V.B. Palomba L. Azzi A. FASEB J. 1997; 11: 181-188Crossref PubMed Scopus (150) Google Scholar) and Chinese hamster fibroblast cell lines (8Keightley J.A. Shang L. Kinter M. Mol. Cell. Proteomics. 2004; 3: 167-175Abstract Full Text Full Text PDF PubMed Scopus (58) Google Scholar). An antioxidant role of AR is also in accord with our observation that inhibition of the enzyme increases 4-hydroxy-trans-2-nonenal accumulation in the ischemic heart and abolishes cardioprotection associated with the late phase of ischemic preconditioning (9Shinmura K. Bolli R. Liu S.Q. Tang X.L. Kodani E. Xuan Y.T. Srivastava S. Bhatnagar A. Circ. Res. 2002; 91: 240-246Crossref PubMed Scopus (112) Google Scholar). In addition, because of its ability to catalyze the reduction of glucose, AR also regulates the flux of glucose in the heart and inhibition of the enzyme has been shown to prevent myocardial ischemia-reperfusion injury by increasing glycolysis and preserving NADH/NAD+ levels (13Hwang S. S. S. R. FASEB J. 2002; PubMed Scopus Google Scholar, R. S. 1997; PubMed Scopus Google Scholar, R. S. J. 275: Google Scholar). the role of the enzyme in the heart is and in by and mechanisms its activity. Aldose reductase is a that to the reductase S.K. Ramana K.V. Bhatnagar A. Endocr. Rev. 2005; 26: 380-392Crossref PubMed Scopus (401) Google Scholar, A. Srivastava S.K. Biochem. Biol. PubMed Scopus Google Scholar). the is in its is enhanced by such as fibroblast and (6Ruef J. Liu S.Q. Bode C. Tocchi M. Srivastava S. Runge M.S. Bhatnagar A. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1745-1752Crossref PubMed Scopus (93) Google Scholar), and such as T. S. J. M. M. A. D. J. Biol. Chem. 1999; Full Text Full Text PDF PubMed Scopus Google Scholar, K.V. Bhatnagar A. Srivastava S.K. FASEB J. 2004; PubMed Scopus Google Scholar). The AR gene is induced in M.B. J. PubMed Google Scholar) a C. J.M. J.A. A. S. A. 2004; PubMed Scopus Google Scholar), which the at the of the AR AR is also to and of the enzyme has been T. Liu S.Q. West M. V. Bhatnagar A. PubMed Scopus Google Scholar). However, such mechanisms AR activity under conditions of oxidative stress or the of activated and of AR in and Srivastava S.K. PubMed Scopus (58) Google Scholar, Biochem. PubMed Scopus Google Scholar, Biochem. PubMed Scopus Google Scholar, S.K. S. A. PubMed Scopus Google Scholar, S.K. J. M.B. PubMed Scopus Google Scholar) and in the ischemic heart (13Hwang S. S. S. R. FASEB J. 2002; PubMed Scopus Google Scholar). AR from that could be to the of activated and of the enzyme Srivastava S.K. PubMed Scopus (58) Google Scholar, Biochem. PubMed Scopus Google Scholar, Biochem. PubMed Scopus Google Scholar, S.K. J. M.B. PubMed Scopus Google Scholar). In the of the activated of the enzyme is of an activated enzyme is its to inhibition by such as sorbinil. of the activated enzyme could be by its cysteine residues A. Liu S. Srivastava S.K. Mol. Google Scholar, A. Liu S.Q. Srivastava S.K. PubMed Scopus Google Scholar, A. Srivastava S. Petrash J.M. Bhatnagar A. Srivastava S.K. 1997; PubMed Scopus Google Scholar, S.Q. Bhatnagar A. Srivastava S.K. PubMed Scopus Google Scholar, S. Dixit B.L. Ramana K.V. A. D. A. Petrash J.M. Bhatnagar A. Srivastava S.K. Biochem. J. PubMed Google Scholar) or of cysteine to J.M. C.S. Bhatnagar A. Liu S. Srivastava S.K. J. Biol. Chem. Full Text PDF PubMed Google Scholar), the in of activated AR has not been to the of AR we in enzyme activity Our that ischemia AR by modifying its cysteine residues to sulfenic acids. of been as an K. Srivastava S. Bhatnagar A. Circulation. 2005; Scholar). CHAPS, N-(2-mercaptoproprionyl)glycine and from was a from and from against rat AR from enhanced and from of ex from and in the as A. J. 26: PubMed Scopus Google Scholar, S. A. Srivastava S.K. Bhatnagar A. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). the hearts at a of with Krebs-Henseleit buffer, in glucose and with a of and of for was in the an in the and to a of and the was and for heart of the In rat hearts for with Krebs-Henseleit or KH or In the hearts for with KH or KH or In the hearts with KH for subjected to ischemia for and for in with an and by of The with a was to of The was a the or and the to the a was under the coronary and the of the a to a for coronary occlusion for the was and the hearts subjected to of reperfusion. The of the ischemic of the was with a hearts as The hearts and from the ischemic and of the in and at of hearts and in of and for at The was with at for in the and was in a at and of and in was used as a reagent of AR was in of NEM, and The was at for at and the was used for AR activity. the was with for at was by a with Enzyme activity was at in a of of and The was by the of oxidation of at for The of the was at of of was in and in of at for at and the was with of and of The levels as S. PubMed Google Scholar). and was in of the NEM, and at for at and the and with to the The was with and in of and to of with CHAPS, and and of proteins the at with a of the in and for The in and and the of a with and subjected to electrophoresis in the The proteins and with T. Liu S.Q. West M. V. Bhatnagar A. PubMed Scopus Google Scholar). to a of and and used for the for with by of of and the under in was to the and the was at The was with a of a in a a The which a laser was was by data at and of of of and was used for was to with and data at a of by from to in the as a with a of with in for data analysis the was a with The was with the The was a at a of The as and at the of the range of The was with in used to to a In to the data the of the of the as and by analysis of for multiple or by for was at in AR activity in the homogenates from hearts subjected to ischemia or ischemia-reperfusion ex or coronary occlusion or in situ shown in homogenates from hearts subjected to of ischemia a increase in AR activity. activation was of ischemia The increase in AR activity in ischemic hearts was by a increase in further in AR activity was upon to a in from the ischemic of hearts subjected to of coronary occlusion a increase in AR activity and than a increase in myocardial as with hearts The enzyme activity in hearts for of coronary occlusion the from the ischemic was to further metabolism or indicate that ischemia ex vivo, or coronary occlusion in situ increase myocardial AR activity and of AR from AR is by ischemia, we the and the sensitivity of the enzyme to and that AR is to such as A. Srivastava S.K. Biochem. Biol. PubMed Scopus Google Scholar). with we that of the to a increase in AR activity in homogenates from and the ischemic that ischemic activation not the sensitivity of the enzyme to the sensitivity of AR to inhibition we used which AR with a of A. Liu S.Q. Srivastava S.K. Biochem. 39: PubMed Scopus Google Scholar). also aldehyde reductase with A. Liu S.Q. Srivastava S.K. Biochem. 39: PubMed Scopus Google Scholar), is or aldehyde reductase activity in the rat heart S. A. Srivastava S.K. Bhatnagar A. J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). In heart AR activity was inhibited by in the of but the of inhibited AR in homogenates of ischemic hearts by that ischemia the sensitivity of AR to inhibition by sorbinil. Our studies that AR to its cysteine residues S.K. Ramana K.V. Bhatnagar A. Endocr. Rev. 2005; 26: 380-392Crossref PubMed Scopus (401) Google Scholar, A. Srivastava S.K. Biochem. Biol. PubMed Scopus Google Scholar). we AR activation in the ischemic heart is to oxidation of its cysteine we AR activity in homogenates from and ischemic hearts that with for at was by and AR activity was shown in activation of AR, and the enzyme was inhibited to by sorbinil. The ability of to activation and sensitivity of AR in ischemic heart homogenates that ischemic activation of AR is to the oxidative of its cysteine of AR from the the of activated AR, in the homogenates of and ischemic in the Km of AR from the ischemic and However, the Vmax in ischemic heart homogenates as with from the that ischemic activation of AR is to an increase in of the homogenates with the Km of AR in and ischemic but decreased the Vmax in and ischemic hearts that a of AR in the heart may be in the activated and that of the enzyme is increased in the ischemic of aldose reductase from and ischemic the heart and the ischemic Vmax Vmax the heart and the ischemic Vmax Vmax in a Activation of AR by we activation of AR is by the reactive oxygen species generated in the ischemic shown in the to hearts subjected to of ischemia a increase in by the levels in the increase in was in hearts with a superoxide radical of hearts with to a in AR to inhibition of However, with AR activation in the ischemic heart and the of AR activity and from ischemic hearts to from the hearts with KH the hearts with shown in treatment with a in AR activity and accumulation in the treatment of the ischemic heart an in the AR activity and the notion that AR is to oxidation and that the enzyme is activated in the ischemic heart by a AR by hydrogen peroxide is the in J.M. Rev. 487-504Crossref PubMed Scopus Google Scholar), we H2O2 activate recombinant AR in of recombinant AR with H2O2 for at in a increase in AR activity The activated enzyme was to sorbinil. of the activated with AR activation and the sensitivity of the enzyme to that AR is activated upon with H2O2 the of AR the and the was with a sulfenic acid-specific A. J. V. D. Biochemistry. 1999; 38: PubMed Scopus Google Scholar). of the enzyme with not enzyme activity or the enzyme was with a in enzyme activity was and the enzyme activity was to inhibition by These suggest that H2O2 AR by its cysteine to sulfenic which with dimedone. the of AR the AR was by shown in the of the AR a to a of which is an of the of An was at The of is of the AR with H2O2 in the of a with a of and a with a of The increase in the to the of oxygen to the which could be to the formation of sulfenic acids or in the AR was with and by shown in AR with a with a of with the of to treatment of the enzyme with AR by H2O2 These suggest that treatment with H2O2 in the formation of cysteine sulfenic acids the AR of AR in the AR activation in the ischemic heart is to homogenates from and ischemic hearts with dimedone. shown in not AR activity in heart but inhibited the enzyme activity in the homogenates from ischemic that the cysteine sulfenic acids generated in AR from the ischemic with observation treatment with increased sensitivity of AR in ischemic that a of AR is and enzyme the activity not inhibited by was to the of a native of the the of AR in the ischemic from the and ischemic or hearts subjected to coronary occlusion in situ as as in the of prevent of and the proteins two-dimensional The for or used for of the proteins from the and hearts to from hearts subjected to ischemia ex or coronary occlusion an with than the native to native or AR from the with and by These with rat AR and to of the The to residues of the cysteine Cys-298 and at the of by of the covalent with suggests that residues in in the analysis of the to the activated AR from the hearts subjected to ischemia with of the AR In in the to residues and and analysis revealed that and in the to acids and Cys-298 and in the to the acids to the sulfenic acids. to the analysis of the from the hearts that residues Cys-298 and in by NEM, in of the from the hearts subjected to coronary Cys-298 and to the sulfenic acids data indicate that cysteine residues of AR, Cys-298 and in the in or hearts and that residues to sulfenic acids in the ischemic analysis of aldose reductase in the ischemic from hearts subjected to ischemia ex or coronary occlusion in situ by two-dimensional The and the to the native AR and and by The of the to the from ischemic and coronary hearts indicate by NEM, or sulfenic acids. The AR from and ischemic hearts in the analysis of AR from rat heart homogenates in a The of that AR is activated in the ischemic heart and that the increase in AR activity could be to the oxidation of the cysteine residues of the enzyme to sulfenic acids. that activated and of AR in enzyme or in (13Hwang S. S. S. R. FASEB J. 2002; PubMed Scopus Google Scholar, Srivastava S.K. PubMed Scopus (58) Google Scholar, Biochem. PubMed Scopus Google Scholar, Biochem. PubMed Scopus Google Scholar, S.K. S. A. PubMed Scopus Google Scholar, S.K. J. M.B. PubMed Scopus Google Scholar), the evidence for the that AR is activated in the ischemic heart by a In to the of evidence that formation is an in of that regulates cellular to oxidative stress A. J. V. D. Biochemistry. 1999; 38: PubMed Scopus Google Scholar, P.A. A. Rev. 2004; PubMed Scopus Google Scholar). The lines of evidence that AR activation in the ischemic heart is to a sulfenic These the that: antioxidant prevented AR activation in the ischemic reduction with AR AR was activated by H2O2 with formation of sulfenic the and the ischemic, but not the or the inhibited by the sulfenic acid-specific and of AR from the hearts subjected to ischemia ex or in situ an increase in with the formation of sulfenic acids. suggest that in the ischemic heart oxidation of the cysteine residues of AR to sulfenic acids. acids of the H2O2 and cysteine oxidants such as and could also cysteine to a sulfenic P.A. A. Rev. 2004; PubMed Scopus Google Scholar). sulfenic been in the of multiple and and of cysteine has also been to oxidative in to of and A. J. V. D. Biochemistry. 1999; 38: PubMed Scopus Google Scholar) and in the activity of the C. J. M.B. E. S. A. 2005; 102: PubMed Scopus Google Scholar) and P.A. A. Rev. 2004; PubMed Scopus Google Scholar). the role of sulfenic acids in and is residues of and or proteins involved in cell or metabolism glutathione and could be in A. J. V. D. Biochemistry. 1999; 38: PubMed Scopus Google Scholar). In addition, in cell sulfenic formation has been to activation S. S. L. M. Cell. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar) and the of by the J. Biol. Chem. Full Text Full Text PDF PubMed Scopus Google Scholar). However, evidence for the formation of sulfenic acids in in situ is of the hearts with of H2O2 has been shown to cysteine sulfenic acids in proteins S. A. 2004; PubMed Scopus Google Scholar), is such of H2O2 in situ and under or conditions the of H2O2 in is to to In our observation that the cysteine residues of AR to sulfenic acids in the ischemic heart the that the levels of generated in the ischemic heart to to sulfenic acids. of AR to in the hearts subjected to ischemia in or ex that is not oxygen that in ex or in of the reactive cysteine residues to has been for that was from the rat ischemia and M. S.J. J. A. 2002; PubMed Scopus Google Scholar), that ischemia-reperfusion as as myocardial ischemia is by an increase in However, which proteins by antioxidant AR is in the which is in glutathione and its oxidation is and the of the enzyme unclear. sulfenic acids could be to or to cysteine by or In addition, cysteine sulfenic acids could with glutathione to or could be to or acids. In proteins such as A. J.A. D. PubMed Scopus Google Scholar, M. D. R. PubMed Scopus Google Scholar) sulfenic acids from further oxidation and in a the the sulfenic of AR is not in the heart ischemia suggests that the cysteine residues of AR in an that not oxidation to and but also to the The of AR an that to a S.K. Ramana K.V. Bhatnagar A. Endocr. Rev. 2005; 26: 380-392Crossref PubMed Scopus (401) Google Scholar). The of the enzyme The Cys-298 and the of the in a that is from the upon The cysteine and in the PubMed Scopus Google Scholar). the enzyme could a of In our we that oxidation of Cys-298 is to increase AR activity and to the sensitivity of the enzyme to A. Liu S. Srivastava S.K. Mol. Google Scholar, A. Liu S.Q. Srivastava S.K. PubMed Scopus Google Scholar, J.M. C.S. Bhatnagar A. Liu S. Srivastava S.K. J. Biol. Chem. Full Text PDF PubMed Google Scholar). of of AR in the ischemic we suggest that the of Cys-298 could for the in the and the sensitivity of the may be in the activated of the In to sulfenic AR could also be A. Srivastava S. Petrash J.M. Bhatnagar A. Srivastava S.K. Biochemistry. 1997; PubMed Scopus Google Scholar), or S. Dixit B.L. Ramana K.V. A. D. A. Petrash J.M. Bhatnagar A. Srivastava S.K. Biochem. J. PubMed Google Scholar). of AR has been in with K.V. D. Srivastava S. Bhatnagar A. Srivastava S.K. FASEB J. PubMed Scopus Google Scholar). However, of glutathione to the cysteine AR activity A. Srivastava S. Petrash J.M. Bhatnagar A. Srivastava S.K. Biochemistry. 1997; PubMed Scopus Google Scholar); that could for ischemic activation of the which to an increase in the activity of the enzyme S. Dixit B.L. Ramana K.V. A. D. A. Petrash J.M. Bhatnagar A. Srivastava S.K. Biochem. J. PubMed Google Scholar), could in for AR activation and increased accumulation in the ischemic However, the of the enzyme with of recombinant AR by increases the Km of AR for S. Dixit B.L. Ramana K.V. A. D. A. Petrash J.M. Bhatnagar A. Srivastava S.K. Biochem. J. PubMed Google Scholar), which was not the for the activated enzyme from the ischemic heart is by DTT, was to the enzyme from the ischemic heart was not The of the activated to reduction is with sulfenic formation which is under reducing sulfenic formation than to ischemic activation of AR is further supported by the observation that the enzyme in ischemic not heart homogenates was inhibited by the sulfenic acid-specific dimedone. we the that in the ischemic AR and to sulfenic acids. for has been shown that formation is upon M. S.J. J. A. 2002; PubMed Scopus Google Scholar), but in our with AR in we evidence for the formation of sulfenic or in the of could be generated in the ischemic to the role of and in AR evidence the that ischemia increases and that oxidative stress is a of myocardial ischemia-reperfusion injury J.M. Rev. 487-504Crossref PubMed Scopus Google Scholar, K. Circulation. PubMed Scopus Google Scholar). is the observation that antioxidant prevent ischemic However, oxidative stress a of antioxidant studies report that of ischemia increase to a ischemic and that is by in the ischemic heart R. Circ. Res. 2000; PubMed Scopus Google Scholar). the mechanisms by which oxidative stress antioxidant not increases in antioxidant to of antioxidant to an increase in the activity of antioxidant proteins an for to oxidative In activation of AR ischemia may of antioxidant our observation that inhibition of AR activation of and K.V. Bhatnagar A. Srivastava S.K. FASEB J. 2004; PubMed Scopus Google Scholar, K.V. D. Srivastava S. Bhatnagar A. Srivastava S.K. J. Biol. Chem. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar, K.V. Srivastava S. Bhatnagar A. Srivastava S.K. 2004; PubMed Scopus Google Scholar, K.V. R. West M.B. Bhatnagar A. Srivastava S.K. 2005; PubMed Scopus Google Scholar) and abolishes ischemic preconditioning (9Shinmura K. Bolli R. Liu S.Q. Tang X.L. Kodani E. Xuan Y.T. Srivastava S. Bhatnagar A. Circ. Res. 2002; 91: 240-246Crossref PubMed Scopus (112) Google Scholar), we that activation of AR in the ischemic heart by oxidation of its cysteine residues to sulfenic acids may be to a cellular of by such as ischemic preconditioning or increased may be a of glucose metabolism An increase in AR activity in the ischemic heart be to the of glucose for a AR activation could to myocardial is with the of and (13Hwang S. S. S. R. FASEB J. 2002; PubMed Scopus Google Scholar, R. S. 1997; PubMed Scopus Google Scholar, R. S. J. 275: Google Scholar) that inhibition of AR injury in ex of The role of glycolysis ischemia and glycolysis is to in the ischemic accumulation of injury Circ. Res. PubMed Scopus Google Scholar). the of ischemic preconditioning associated with a in glycolysis M. C. M. J. Biol. Chem. 2002; Full Text Full Text PDF PubMed Scopus Google Scholar), which may be a of increased glucose by activated the role of AR in myocardial metabolism ischemia to be in to the of the activation of enzyme by of its cysteine
47
S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death
Zezong Gu, Marcus Kaul, Boxu Yan et al. · Science · 2002 · 948 citations
Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B
Rob L. M. van Montfort, Miles Congreve, Dominic Tisi et al. · Nature · 2003 · 644 citations